Chris Seper runs MedCityNews.com and contributes regularly to the site. He is the vice president of healthcare for Breaking Media, MedCity's corporate owners. Reach him at [email protected].
Also, a new fund to help life science startups out of University College of London, some numbers on direct-to-consumer lab revenues, and a U.K. sugar tax policy that could be here soon.
Healthcare needed a Chuck Norris.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Also, a new song from ZDogg, Baidu is in trouble for its medical claims and LifeWatch gets a new FDA clearance.
Last call for #jpm16. Also, iHealthBeat is shutting down, what's next for BioMarin and meet the new Centers for Common Disease Genomics.
How did tech get so hot when the deals in biotech are so much bigger?
It's not dumb money. They are seeing things differently.
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
At least genomics and health insurers are smiling.
EVERYONE SAID THE FUN WOULD NEVER END!!!!
Also, learn how consumers are gaming Obamacare, the next moves to get better reimbursement for telemedicine, and meet some impressive new venture partners.
Here's your morning JPM Healthcare 2016 roundup as Day 1 gets underway.
We will highlight Build My Health's revenue practice management tools, which could help physician practices add up to $250,000 to their practices.
Also, BioAtla closes a major round, Pfizer jacks up it's U.S. drug prices and bad advice on forming your digital health startup.
Also, a message on price-hikes from Valeant's interim CEO, Martin Shkreli's E-Trade Account, and some context for AHIP after Aetna's departure.
Also, Withings unveils a smart thermometer at CES, BIO changes its name, and a new British-backed sugar-measuring smartphone app.
Plus, Epic's growth, moves by Pershing Square on Valeant and the battle for the soul of BMJ.
The votes are in: 23AndMe is going to shock the world in 2016.